Fulgent generated Q4 2025 revenue of 83336000, up 9% year-over-year, with GAAP gross margin of 39.1%. The company reported a GAAP net loss of 23418000 and a non-GAAP net income of 5154000, while adjusted EBITDA was negative 4537000.

Fulgent reported 17% year-over-year revenue growth in Q3 2025, with GAAP losses narrowing and non-GAAP profitability achieved through margin expansion and cost controls.

Fulgent Genetics reported a total revenue of $81.8 million for the second quarter of 2025, with core revenue growing 16% year-over-year to $81.7 million. The company experienced a GAAP net loss of $19.0 million, or ($0.62) per share, which included a one-time charge. Non-GAAP income was $2.1 million, or $0.07 per share. The company ended the quarter with $777.5 million in cash, cash equivalents, restricted cash, and investments in marketable securities.

Fulgent Genetics reported Q4 2024 revenue of $76.2 million, with core revenue growing 14% year-over-year to $76.0 million. The company experienced a GAAP loss of $5.9 million, or ($0.19) per share, but a non-GAAP income of $1.2 million, or $0.04 per share. They ended the year with $828.6 million in cash, cash equivalents, and investments.

Fulgent Genetics reported a total revenue of $71.7 million for Q3 2024, with core revenue growing 9% year-over-year. The company's GAAP loss was $14.6 million, or ($0.48) per share, while non-GAAP income was $9.4 million, or $0.31 per share. Fulgent is reiterating its full-year 2024 core revenue guidance of $280 million and improving its earnings per share guidance for 2024.

Fulgent Genetics reported a GAAP loss of $8.7 million, or ($0.29) per share, but experienced growth in core revenue, which increased by 5% year-over-year to $70.2 million. The company reiterated its full-year 2024 core revenue guidance of $280 million and improved its earnings per share guidance for 2024.

Fulgent Genetics reported a total revenue of $64.5 million and a GAAP loss of $13.5 million, or $0.45 per share, for the first quarter of 2024. Core revenue grew 1% year-over-year to $63.2 million. The company reiterates full year 2024 core revenue guidance of $280 million.

Fulgent Genetics reported a GAAP loss of $128.1 million, or $4.30 per share, but non-GAAP income of $8.3 million, or $0.28 per share. Total revenue was $70.5 million, with core revenue growing 21% year-over-year to $66.5 million. The company ended the year with $847.7 million in cash, cash equivalents, and investments.

Fulgent Genetics reported a total revenue of $85 million for Q3 2023, with core revenue growing 17% year-over-year to $66 million. The company experienced a GAAP loss of $13.1 million, or $0.44 per share, and a non-GAAP loss of $11.7 million, or $0.39 per share. Despite the losses, Fulgent generated $10.2 million in cash flow from operations and holds $851 million in cash, cash equivalents, and investments.

Fulgent Genetics reported a total revenue of $68 million for Q2 2023. Core revenue grew 48% year-over-year to $67 million. The company experienced a GAAP loss of $11.2 million, or $0.38 per share, and a non-GAAP loss of $2.4 million, or $0.08 per share.

Fulgent Genetics reported a GAAP loss of $15.3 million, or $0.52 per share, and a non-GAAP loss of $6.5 million, or $0.22 per share. However, core revenue grew 150% year-over-year to $62.7 million, and total revenue was $66.2 million. The company raised its full-year 2023 core revenue guidance to $250 million.

Fulgent Genetics reported a decline in total revenue for Q4 2022, with a GAAP loss of $23.8 million and a non-GAAP loss of $14.2 million. However, core revenue grew by 97% year-over-year. The company is focused on transforming into a precision medicine company.

Fulgent Genetics reported a revenue of $105.7 million for Q3 2022, a decrease compared to $227.9 million in Q3 2021. However, core revenue, excluding COVID-19 testing, grew 110% year-over-year to $56.0 million. The company reported a GAAP income of $1.7 million, or $0.06 per share, and a non-GAAP income of $9.8 million, or $0.32 per share.

Fulgent Genetics reported a revenue of $125.3 million for Q2 2022, a decrease from $153.6 million in Q2 2021. However, core revenue grew by 102% year-over-year to $45.3 million. GAAP income was $11.5 million, or $0.37 per share, and non-GAAP income was $24.3 million, or $0.78 per share.

Fulgent Genetics reported a revenue of $320.3 million for Q1 2022, with core revenue excluding COVID-19 NGS testing growing 59% year-over-year to $25.1 million. The company has raised its full-year revenue outlook to $660 million and core revenue outlook to $180 million.

Fulgent Genetics reported strong Q4 2021 results, with revenue of $251.7 million and core revenue growth of 234%. The company's GAAP income was $104.3 million, or $3.34 per share, and non-GAAP income was $108.7 million, or $3.48 per share.

Fulgent Genetics reported strong Q3 2021 results with revenue growing 124% year-over-year to $227.9 million. Core revenue increased by 292% year-over-year to $40.1 million. The company raised its full-year revenue guidance to $930 million, reflecting strength in both its core and COVID-19 businesses.

Fulgent Genetics reported a remarkable 790% year-over-year revenue increase, reaching $153.6 million, driven by growth in both core NGS business and COVID-19 testing. The company expanded its platform capabilities and reach through acquisitions and strategic agreements.

Fulgent Genetics reported record first quarter revenue of $359.4 million, a 4,500% increase year-over-year. The company's GAAP income was $200.7 million, or $6.52 per share, and non-GAAP income was $202.9 million, or $6.59 per share.

Fulgent Genetics reported a record fourth quarter with revenue of $295.0 million, an increase of 3,400% year-over-year. GAAP income was $166.3 million, or $6.16 per share, and non-GAAP income was $167.5 million, or $6.20 per share.

Fulgent Genetics reported record third-quarter revenue of $101.7 million, an 883% increase year-over-year. GAAP earnings were $46.6 million, or $1.98 per share, and non-GAAP earnings were $49.0 million, or $2.08 per share. The company raised its full-year revenue guidance to $235 million.

Fulgent Genetics reported record second-quarter revenue of $17.3 million, a 105% increase year-over-year. GAAP earnings were $3.3 million, or $0.14 per share, and non-GAAP earnings were $4.0 million, or $0.17 per share. The company's growth was fueled by its COVID-19 testing services and a rebound in traditional genetic testing orders.

Fulgent Genetics reported a 44% year-over-year increase in revenue, totaling $7.8 million for the first quarter of 2020. The company launched multiple COVID-19 screening tests and saw strong demand, which helped offset challenges in its core rare disease, oncology, and reproductive health businesses. The company made significant investments in the research, development, and launch of COVID-19 tests, impacting the bottom line.

Fulgent Genetics announced its Q4 and Full Year 2019 financial results, with Q4 revenue reaching $8.4 million, a 48% increase year-over-year. The company reported a GAAP loss of $296,000, or $0.01 per share, and a non-GAAP income of $778,000, or $0.04 per share for the quarter.